65,437 trials
Non-relapsing Secondary Progressive Multiple Sclerosis
Primary: Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) — 11.97; 12.04 months — p=0.0026
Dementia
Primary: Number of Patients Who Completed the Symptom Management at the End of Life for Dementia Scale (SM-EOLD) — 14; 16; 6; 5 Participants
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses — 0.109; 0.108 relapses per participant year — p=0.9758
Saliva · Dental Crown · Nickel Sensitivity
Primary: IL-2, IL-5, IL-17 Expression Level (Fold Change) — 1.2; 1.8; 4.5 Fold Change
Type 1 Diabetes · Hypoglycemia
Primary: The Number of Participants Recruited to Reach 20 Participants That Complete the Intervention — 20 Participants
Prostate Cancer · Non-metastatic Prostate Cancer · Metastatic Prostate Cancer
Primary: Number of Men Who Consented to Inclusion in PROSPECT Study Out of Total Number of Patients Approached — 36.2 percentage of participants
Rhabdomyosarcoma
Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients
Heart Failure NYHA Class II · Heart Failure NYHA Class III · Heart Failure NYHA Class IV
Primary: Physician Overall Satisfaction With the We Chatt Intervention Based on the Post Clinician Survey — 57.4 score on a scale
Tobacco-Related Carcinoma
Primary: Visual Attention - Dwell Time — 1871.00; 1881.01; 1695.21; 1603.15 milliseconds
Short Bowel Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) — 9; 5; 3; 1 Participants
Opioid Misuse · Chronic Pain
Primary: Feasibility of Algorithms — 7; 13 Participants
Mild Cognitive Impairment · Mild Dementia · Alzheimer's Disease
Primary: Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score — 3.8; 5.3 score on a scale — p=0.1642
Vascular Access Device Complications
Primary: Percent Eligible Patients That Agreed to Participate — 80 percentage of eligible patients agreed t
Facial Rhytides · Skin Folds · Loss of Volume and Skin Quality
Primary: Change From Baseline in the Rasch-transformed Score of the FACE-Q Satisfaction With Facial Appearance Scale. — 46.6 units on a scale — p=<0.0001
PTSD · Depression
Primary: PCL-5 Total Score Change — 50.1; 49.2 Units on a scale (PCL-5)